针对癌症药物过敏的一袋方案:安全性和有效性的元分析
Andrés Noyola-Pérez1, Sandra N González-Díaz1, Carlos Macouzet-Sánchez1
1Universidad Autónoma de Nuevo León (UANL), Regional Center for Allergy and Clinical Immunology, Faculty of Medicine and University Hospital "Dr. José Eleuterio González", Monterrey, Nuevo León, Mexico.
概括
快速降低药物敏感性的一袋方案 (1BP) 对化学疗法和单克隆抗体的过敏反应安全有效. 这种简化方法通过简化程序,提高了癌症治疗的可访问性.
科学领域:
- 在瘤学瘤学.
- 临床药理学 临床药理学
- 免疫学 免疫学 免疫学
背景情况:
- 对化疗的过敏反应 (HSR) 在全球范围内对癌症治疗构成重大障碍.
- 传统的快速药物脱敏 (RDD) 三袋协议 (3BPs) 在操作上很复杂,可能会加剧健康差异.
研究的目的:
- 系统地评估化学疗法和单克隆抗体的HSR患者的RDD的一袋方案 (1BP) 的安全性,完成率和持续时间.
- 将1BP结果与传统的3BP结果进行比较.
主要方法:
- 进行了元分析,搜索了多个数据库 (MEDLINE,Embase,科学网,CENTRAL).
- 包括详细介绍HSRs对化疗和单克隆抗体的1BP的研究.
- 数据提取和选由四名审查员独立进行,重点关注完成率,安全性和协议持续时间.
主要成果:
- 分析包括16项研究,涉及975名患者和4473次RDD手术.
- 1BP的综合完成率为99.7%,在各类药物中一致.
- 突破反应发生在12%的RDD中,大多为轻度至中度 (0.4%严重);与3BP相比,没有发现完成率的显著差异.
结论:
- 一袋协议 (1BP) RDD证明了过敏反应的高安全性和完成率.
- 简化的RDD协议通过控制的暴露动力学提高了患者的安全性,减少了复杂性.
- 1BP简化了工作流程,优化了资源配置,并改善了获得必要的癌症治疗的机会.
相关概念视频
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
180
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
180
Hazard Ratio
257
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
257
Combined Effects of Drugs: Synergism
4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.8K


